PHAXIAM Therapeutics S.A. (0QSS.L)
EUR 1.76
(1.03%)
EUR 1.76
(1.03%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 24.98 Million EUR | -14.36% |
| 2022 | 29.17 Million EUR | -47.26% |
| 2021 | 55.31 Million EUR | -18.12% |
| 2020 | 67.55 Million EUR | 3.71% |
| 2019 | 65.14 Million EUR | 37.8% |
| 2018 | 47.27 Million EUR | 40.17% |
| 2017 | 33.72 Million EUR | 30.79% |
| 2016 | 25.78 Million EUR | 42.12% |
| 2015 | 18.14 Million EUR | 68.46% |
| 2014 | 10.77 Million EUR | 28.79% |
| 2013 | 8.36 Million EUR | 31.12% |
| 2012 | 6.37 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.87 Million EUR | -9.09% |
| 2024 Q2 | 5.87 Million EUR | 0.0% |
| 2023 Q2 | 12.41 Million EUR | 94.67% |
| 2023 FY | 23.8 Million EUR | -18.39% |
| 2023 Q3 | 5.86 Million EUR | -52.74% |
| 2023 Q4 | 6.46 Million EUR | 10.16% |
| 2023 Q1 | 6.37 Million EUR | -7.79% |
| 2022 Q3 | 8.92 Million EUR | -57.36% |
| 2022 FY | 29.17 Million EUR | -47.26% |
| 2022 Q4 | 6.91 Million EUR | -22.48% |
| 2022 Q2 | 20.92 Million EUR | 60.25% |
| 2022 Q1 | 13.05 Million EUR | -50.87% |
| 2021 Q3 | 17.77 Million EUR | -38.17% |
| 2021 FY | 55.31 Million EUR | -18.12% |
| 2021 Q4 | 26.57 Million EUR | 49.53% |
| 2021 Q1 | 14.68 Million EUR | -55.3% |
| 2021 Q2 | 28.74 Million EUR | 95.73% |
| 2020 Q4 | 32.85 Million EUR | 84.48% |
| 2020 FY | 67.55 Million EUR | 3.71% |
| 2020 Q1 | 19.83 Million EUR | -39.93% |
| 2020 Q2 | 34.78 Million EUR | 75.32% |
| 2020 Q3 | 17.8 Million EUR | -48.8% |
| 2019 Q1 | 14.02 Million EUR | 34.86% |
| 2019 Q2 | 32.11 Million EUR | 129.07% |
| 2019 FY | 65.14 Million EUR | 37.8% |
| 2019 Q4 | 33.02 Million EUR | 123.35% |
| 2019 Q3 | 14.78 Million EUR | -53.96% |
| 2018 Q4 | 10.39 Million EUR | -6.59% |
| 2018 Q3 | 11.13 Million EUR | 2.76% |
| 2018 Q2 | 10.83 Million EUR | 3.52% |
| 2018 Q1 | 10.46 Million EUR | -21.58% |
| 2018 FY | 47.27 Million EUR | 40.17% |
| 2017 Q4 | 13.34 Million EUR | 67.27% |
| 2017 Q1 | 7.75 Million EUR | 14.43% |
| 2017 Q2 | 8.21 Million EUR | 5.95% |
| 2017 FY | 33.72 Million EUR | 30.79% |
| 2017 Q3 | 7.97 Million EUR | -2.89% |
| 2016 Q2 | 7.92 Million EUR | 55.01% |
| 2016 Q4 | 6.77 Million EUR | 0.0% |
| 2016 Q3 | 6.77 Million EUR | -14.46% |
| 2016 FY | 25.78 Million EUR | 42.12% |
| 2016 Q1 | 5.11 Million EUR | -0.62% |
| 2015 Q4 | 5.14 Million EUR | 0.0% |
| 2015 Q3 | 5.14 Million EUR | 26.12% |
| 2015 FY | 18.14 Million EUR | 68.46% |
| 2015 Q2 | 4.07 Million EUR | 0.0% |
| 2015 Q1 | 4.07 Million EUR | 18.41% |
| 2014 Q4 | 3.44 Million EUR | 0.0% |
| 2014 Q1 | 1.94 Million EUR | -12.97% |
| 2014 Q3 | 3.44 Million EUR | 77.33% |
| 2014 Q2 | 1.94 Million EUR | 0.0% |
| 2014 FY | 10.77 Million EUR | 28.79% |
| 2013 FY | 8.36 Million EUR | 31.12% |
| 2013 Q2 | 1.95 Million EUR | 0.0% |
| 2013 Q3 | 2.23 Million EUR | 14.42% |
| 2013 Q1 | 1.95 Million EUR | 21.92% |
| 2013 Q4 | 2.23 Million EUR | 0.0% |
| 2012 Q4 | 1.59 Million EUR | 0.0% |
| 2012 FY | 6.37 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Boiron SA | 317.27 Million EUR | 92.125% |
| Laboratorios Farmaceuticos Rovi, S.A. | 263.09 Million EUR | 90.503% |
| Vetoquinol SA | 217.11 Million EUR | 88.492% |
| Valneva SE | 134.92 Million EUR | 81.481% |
| AB Science S.A. | 14.01 Million EUR | -78.268% |
| Nanobiotix S.A. | 62.98 Million EUR | 60.331% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | -1.191% |
| BioSenic S.A. | 7.58 Million EUR | -229.5% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 80.384% |
| Formycon AG | 23.73 Million EUR | -5.28% |